Literature DB >> 7954376

Cisplatin: a clinical review. Part II--Nursing assessment and management of side effects of cisplatin.

M E Cooley1, L Davis, J Abrahm.   

Abstract

Cisplatin is one of the most active cancer treatment agents available. Unfortunately, however, cisplatin causes many untoward side effects. Nurses play a major role in administering cisplatin and in preventing and managing the adverse effects associated with this drug. In order to maximize the quality of life of patients undergoing cisplatin treatment, nurses need a thorough knowledge of its uses, administration, and side effects. This article is the second of a two-part series about cisplatin. Part I provided a review of the mechanism of action, current uses, and administration guidelines. Part II discusses the most common side effects of cisplatin and the appropriate nursing assessment and management of patients undergoing treatment with this agent. In addition, future directions for the use of cisplatin and the use of alternative agents will be discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7954376

Source DB:  PubMed          Journal:  Cancer Nurs        ISSN: 0162-220X            Impact factor:   2.592


  10 in total

1.  Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy.

Authors:  Iryna A Khasabova; Sergey Khasabov; Justin Paz; Catherine Harding-Rose; Donald A Simone; Virginia S Seybold
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

2.  Cell death-inducing effect of novel palladium(II) and platinum(II) complexes on non-small cell lung cancer cells in vitro.

Authors:  Engin Ulukaya; Ferda Ari; Konstantinos Dimas; Mehmet Sarimahmut; Emel Guney; Nikos Sakellaridis; Veysel T Yilmaz
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-02       Impact factor: 4.553

3.  Prospective comparison of transcatheter arterial chemoembolization with Lipiodol-epirubicin and Lipiodol-cisplatin for treatment of recurrent hepatocellular carcinoma.

Authors:  Shinya Sahara; Nobuyuki Kawai; Morio Sato; Hiroki Minamiguchi; Motoki Nakai; Isao Takasaka; Kouhei Nakata; Akira Ikoma; Naohisa Sawa; Tetsuo Sonomura; Shintaro Shirai
Journal:  Jpn J Radiol       Date:  2010-06-30       Impact factor: 2.374

4.  The protective effects of intratympanic dexamethasone and vitamin E on cisplatin-induced ototoxicity are demonstrated in rats.

Authors:  Mustafa Paksoy; Emin Ayduran; Arif Sanlı; Mehmet Eken; Sedat Aydın; Zeynep Alev Oktay
Journal:  Med Oncol       Date:  2010-03-19       Impact factor: 3.064

5.  Selenium Status in Diet Affects Nephrotoxicity Induced by Cisplatin in Mice.

Authors:  Shuang Liu; Xing Wen; Qihan Huang; Minghui Zhu; Jun Lu
Journal:  Antioxidants (Basel)       Date:  2022-06-10

6.  Overproduction of reactive oxygen species - obligatory or not for induction of apoptosis by anticancer drugs.

Authors:  Donika Ivanova; Zhivko Zhelev; Ichio Aoki; Rumiana Bakalova; Tatsuya Higashi
Journal:  Chin J Cancer Res       Date:  2016-08       Impact factor: 5.087

7.  Antitumor Activity of 2,9-Di-Sec-Butyl-1,10-Phenanthroline.

Authors:  Dongsheng Wang; Shifang Peng; A R M Ruhul Amin; Mohammad Aminur Rahman; Sreenivas Nannapaneni; Yuan Liu; Dong M Shin; Nabil F Saba; Jack F Eichler; Zhuo G Chen
Journal:  PLoS One       Date:  2016-12-29       Impact factor: 3.240

8.  Danshen extract circumvents drug resistance and represses cell growth in human oral cancer cells.

Authors:  Cheng-Yu Yang; Cheng-Chih Hsieh; Chih-Kung Lin; Chun-Shu Lin; Bo Peng; Gu-Jiun Lin; Huey-Kang Sytwu; Wen-Liang Chang; Yuan-Wu Chen
Journal:  BMC Complement Altern Med       Date:  2017-12-29       Impact factor: 3.659

9.  Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.

Authors:  Sanjeevani Arora; Joshua Heyza; Hao Zhang; Vivian Kalman-Maltese; Kristin Tillison; Ashley M Floyd; Elaine M Chalfin; Gerold Bepler; Steve M Patrick
Journal:  Oncotarget       Date:  2016-11-15

10.  Gap Junction Intercellular Communication Positively Regulates Cisplatin Toxicity by Inducing DNA Damage through Bystander Signaling.

Authors:  Sanjeevani Arora; Joshua R Heyza; Elaine C Chalfin; Randall J Ruch; Steve M Patrick
Journal:  Cancers (Basel)       Date:  2018-10-02       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.